LAS VEGAS, NV—A meta-analysis presented at PAINWeek 2012 of two OTC doses of ibuprofen showed that 400 mg provided significantly better overall pain relief compared with 200 mg over a 6-hour period.
Tapentadol extended-release tablets is efficacious in the management of moderate-to-severe chronic pain associated with diabetic peripheral neuropathy in adults, according study results presented at PAINWeek 2012.
An orally inhaled dihydroergotamine studied for the rescue treatment of acute migraine exhibited significant pain relief compared with placebo, according to the results of a pivotal phase 3 trial presented at PAINWeek 2012
Only a handful of agents are approved for treating CNS pain and there is little hard data to help diagnosis and treatment, Charles E. Argoff, MD, of the Comprehensive Pain Center at Albany (NY) Medical Center, told attendees of PAINWeek 2012.
Tapentadol therapy has nominal effects on luteinizing hormone and testosterone, in contrast to the opioid-induced androgen deficiency observed with other mu-opioid analgesics, according to study results presented at PAINWeek 2012.
Patients with chronic neuropathic pain can be safely and effectively converted and maintained on hydromorphone extended-release, as shown in a study presented at PAINWeek 2012.
Low levels of vitamin D are related to chronic knee pain, according to a study presented at PAINWeek 2012.
As a first-line option, buprenorphine/naloxone can plausibly be given for opioid dependency through a primary care setting, according to a study presented at PAINWeek 2012.
Opioids play an important role in the treatment of moderate-to-severe pain, but with an increasing market for pain therapies, diversion and abuse have escalated as well, reported Travis Mickle, PhD, of KemPharm, North Liberty, IA , at PAINWeek 2012.
A study comparing tapentadol immediate-release and oxycodone immediate-release in moderate-to-severe, acute low back pain with radicular leg pain demonstrated comparable efficacy, with reduced gastrointestinal side effects seen with the tapentadol immediate-release arm, investigators reported during PAINWeek 2012.
